Meanwhile, the S&P BSE Sensex was down 210.53 points, or 1.12%, to 18,563.71.
On BSE, 1.53 lakh shares were traded in the counter as against an average daily volume of 41,488 shares in the past one quarter.
The stock hit a high of Rs 129.80 and a low of Rs 109 so far during the day. The stock had hit a 52-week high of Rs 152.45 on 17 April 2013. The stock had hit a 52-week low of Rs 78.50 on 18 October 2012.
The stock had underperformed the market over the past one month till 21 June 2013, sliding 12.64% compared with the Sensex's 6.65% fall. The scrip had, however, outperformed the market in past one quarter, rising 2.23% as against Sensex's 0.10% fall.
The small-cap company has an equity capital of Rs 15.82 crore. Face value per share is Re 1.
Fresenius Kabi Oncology reportedly filed an appeal last week against the Securities Exchange Board of India's (Sebi) order related to non-compliance of minimum 25% public shareholding norms and had sought approval for its delisting plans.
More From This Section
Sebi had earlier refused permission to the company for its delisting plans, saying that it had benefited from a specially designed offer-for-sale (OFS) route for expanding the public float of shares.
The company's foreign promoter Fresenius Kabi (Singapore) Pte currently holds 81% stake in the company. While the company had earlier sold 9% promoter stake through an OFS, it later proposed to delist its shares from the stock exchanges rather than selling a further 6% to meet the minimum public shareholding requirement.
Fresenius Kabi (Singapore) Pte had announced delisting plan in April 2013. The foreign promoter had said at that time that it intends to pay an indicative price of up to Rs 130 per share to acquire the shares offered to it in the delisting offer.
Fresenius Kabi Oncology reported net loss of Rs 7.76 crore in Q4 March 2013 as against net profit of Rs 1.68 crore in Q4 March 2012. Net sales declined 32.64% to Rs 70.54 crore in Q4 March 2013 over Q4 March 2012.
Fresenius Kabi Oncology is engaged in cancer research and development of anti-cancer products. The company manufactures active pharmaceutical ingredients (APIs), intermediates and oral & injectable finished dosage forms.
Powered by Capital Market - Live News